The Role of Platelet-Derived Growth Factor Signaling in Healing Myocardial Infarcts
Pawel Zymek, MD*,
Marcin Bujak, MD*,
Khaled Chatila, MD*,
Anna Cieslak, MS*,
Geeta Thakker, PhD ,
Mark L. Entman, MD, FACC* and
Nikolaos G. Frangogiannis, MD, FACC*,*
* Section of Cardiovascular Sciences, the DeBakey Heart Center, Baylor College of Medicine, and the Methodist Hospital, Houston, Texas
Section of Atherosclerosis, the DeBakey Heart Center, Baylor College of Medicine, and the Methodist Hospital, Houston, Texas.

View larger version (161K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 The microvascular network in reperfused mouse infarcts is identified by CD31 immunohistochemistry. (A) CD31 staining of control heart labels the myocardial vasculature. (B) Serial section with omission of the primary antibody serves as a negative control. (C) After 72 h of reperfusion, infarct granulation tissue contains many CD31-positive endothelial cells (arrowheads). (D) After 7 days of reperfusion, the infarcted area contains relatively few capillaries (arrows) and a significant number of coated vessels (arrowheads). Counterstained with eosin (magnification 200x).
|
|

View larger version (54K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Activation of the platelet-derived growth factor receptor (PDGFR)-ß signaling pathway in healing murine myocardial infarcts was detected using immunohistochemical staining with an antibody to phosphorylated PDGFR-ß (pPDGFR-ß). (A) Noninfarcted areas showed minimal staining for pPDGFR-ß. (B) After 7 days of reperfusion, perivascular and mononuclear-like cells (arrowheads) with intense immunoreactivity to pPDGFR-ß were found in the infarcted myocardium. (C) Negative control with omission of the primary antibody shows no staining. Counterstained with eosin (magnification 200x).
|
|

View larger version (118K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 6 Platelet-derived growth factor receptor (PDGFR)-ß inhibition resulted in impaired vascular maturation and enhanced capillary density in the healing infarct. (A) CD31 immunohistochemistry identified the infarct vasculature in immunoglobulin IgG-treated mice (magnification 200x). (B) Numerous coated vessels were noted in the infarct after 7 days of reperfusion (arrows). (C to F) The PDGFR-ß inhibition with the neutralizing antibody APB5 resulted in impaired vascular maturation and in formation of dilated, disorganized, irregularly-shaped vascular structures (arrows). (C, magnification 200x; D to F, magnification 400x). (G to I) Quantitative analysis of total microvascular density (G), density of uncoated vessels (H), and density of coated vessels (I) in the infarct. The PDGFR-ß inhibition significantly increased microvascular density (**p < 0.01 vs. IgG-treated animals) (G) and the number of uncoated vessels (**p < 0.01 vs. IgG-injected mice) (H), but decreased the density of coated vessels (I) in the infarcted area (*p < 0.05 vs. IgG-treated mice). In contrast, PDGFR- inhibition did not affect vascular maturation. Other abbreviations as in Figure 5.
|
|
|